Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933606 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of BNC210 in PTSD
A Phase 2 study, sponsored by Bionomics Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 193
- Enrollment target
NCT02933606 is a Phase 2 study that has completed, run by Bionomics Limited. The registered enrollment target is 193 participants.
The verdict
NCT02933606, a Phase 2 study, has completed, sponsored by Bionomics Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 193 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.
Interventions
- DRUG Placebo
- DRUG BNC210
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2018-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02933606
The ClinicalTrials.gov registry entry for NCT02933606 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bionomics Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02933606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02933606 about?
NCT02933606 is a clinical study titled "Phase II Study of BNC210 in PTSD". This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The secondary objectives of the study are to evaluate the effects...
What is the current status of trial NCT02933606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 193 participants. The study started on 2016-06-30. Estimated completion is 2018-07-25.
What interventions are being tested in trial NCT02933606?
The interventions under investigation include: Placebo (DRUG), BNC210 (DRUG).
Who is sponsoring clinical trial NCT02933606?
This trial is sponsored by Bionomics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.